267 related articles for article (PubMed ID: 15481851)
1. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Finn WF; Joy MS; Hladik G;
Clin Nephrol; 2004 Sep; 62(3):193-201. PubMed ID: 15481851
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
3. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
4. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn WF; Joy MS;
Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
[TBL] [Abstract][Full Text] [Related]
5. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
[TBL] [Abstract][Full Text] [Related]
6. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Finn WF;
Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
[TBL] [Abstract][Full Text] [Related]
7. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
8. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
[TBL] [Abstract][Full Text] [Related]
9. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
Hutchison AJ; Gill M; Copley JB; Poole L; Wilson RJ
BMC Nephrol; 2013 Feb; 14():40. PubMed ID: 23418668
[TBL] [Abstract][Full Text] [Related]
10. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
Al-Baaj F; Speake M; Hutchison AJ
Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
[TBL] [Abstract][Full Text] [Related]
11. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Vemuri N; Michelis MF; Matalon A
BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
[TBL] [Abstract][Full Text] [Related]
12. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
Ohno M; Ohashi H; Oda H; Yokoyama H; Okada M; Nagaya M; Izumi K; Ito H; Katoh S
Perit Dial Int; 2013; 33(3):297-303. PubMed ID: 23209037
[TBL] [Abstract][Full Text] [Related]
13. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
[TBL] [Abstract][Full Text] [Related]
15. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
16. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
17. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
Xu J; Zhang YX; Yu XQ; Liu ZH; Wang LN; Chen JH; Fan YP; Ni ZH; Wang M; Yuan FH; Ding GH; Chen XM; Zhang AP; Mei CL
BMC Nephrol; 2013 Feb; 14():29. PubMed ID: 23379590
[TBL] [Abstract][Full Text] [Related]
18. Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
Wei Y; Kong XL; Li WB; Wang ZS
Ther Apher Dial; 2014 Dec; 18(6):618-22. PubMed ID: 24674384
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
[TBL] [Abstract][Full Text] [Related]
20. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
Hutchison AJ; Laville M;
Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
